In patients with isolated TD, we noticed lower rates of hypovolemia and inflammatory markers (IL-6, PCT) and no need for intensive care and second-line immunomodulatory therapy as compared to AKI-TD subset (Table 4). The gene discussed is IL6; the disease is thanatophoric dysplasia.